Published in J Med Food on January 01, 2004
Dietary agents for chemoprevention of prostate cancer. Cancer Lett (2008) 1.72
Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res (2007) 1.29
Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer (2010) 1.26
A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis (2012) 1.21
Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. J Nutr Biochem (2008) 1.17
Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Invest New Drugs (2005) 1.06
Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model. Carcinogenesis (2011) 1.03
Cancer chemoprevention by pomegranate: laboratory and clinical evidence. Nutr Cancer (2009) 1.01
Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. Growth Horm IGF Res (2009) 1.00
Prostate cancer and the influence of dietary factors and supplements: a systematic review. Nutr Metab (Lond) (2014) 0.98
Pomegranate-mediated chemoprevention of experimental hepatocarcinogenesis involves Nrf2-regulated antioxidant mechanisms. Carcinogenesis (2011) 0.97
Potent health effects of pomegranate. Adv Biomed Res (2014) 0.95
A Comprehensive Review of Punica granatum (Pomegranate) Properties in Toxicological, Pharmacological, Cellular and Molecular Biology Researches. Iran J Pharm Res (2012) 0.95
Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis. Transl Oncol (2012) 0.91
Greco-arab and islamic herbal-derived anticancer modalities: from tradition to molecular mechanisms. Evid Based Complement Alternat Med (2011) 0.90
Preventive and prophylactic mechanisms of action of pomegranate bioactive constituents. Evid Based Complement Alternat Med (2013) 0.88
Nanoparticle delivery of natural products in the prevention and treatment of cancers: current status and future prospects. Cancers (Basel) (2011) 0.87
Ellagitannins in Cancer Chemoprevention and Therapy. Toxins (Basel) (2016) 0.86
Potential Effects of Pomegranate Polyphenols in Cancer Prevention and Therapy. Oxid Med Cell Longev (2015) 0.83
Efficacy and safety of pomegranate medicinal products for cancer. Evid Based Complement Alternat Med (2015) 0.81
Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial. J Cancer (2013) 0.81
Pomegranate and its components as alternative treatment for prostate cancer. Int J Mol Sci (2014) 0.81
Pomegranate extracts and cancer prevention: molecular and cellular activities. Anticancer Agents Med Chem (2013) 0.79
N-myc downstream-regulated gene 1 (NDRG1) mediates pomegranate juice protection from apoptosis in hypoxic BeWo cells but not in primary human trophoblasts. Placenta (2015) 0.78
Punicalagin, a polyphenol in pomegranate juice, downregulates p53 and attenuates hypoxia-induced apoptosis in cultured human placental syncytiotrophoblasts. Am J Physiol Endocrinol Metab (2013) 0.78
Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data. Evid Based Complement Alternat Med (2013) 0.78
Nanoencapsulation of pomegranate bioactive compounds for breast cancer chemoprevention. Int J Nanomedicine (2015) 0.78
A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer. Prostate Cancer Prostatic Dis (2015) 0.78
Carbohydrate-Free Peach (Prunus persica) and Plum (Prunus salicina) [corrected] Juice Affects Fecal Microbial Ecology in an Obese Animal Model. PLoS One (2014) 0.77
Urolithin A causes p21 up-regulation in prostate cancer cells. Eur J Nutr (2015) 0.77
A Perspective on Prostate Carcinogenesis and Chemoprevention. Curr Pharmacol Rep (2015) 0.76
Food-based natural products for cancer management: Is the whole greater than the sum of the parts? Semin Cancer Biol (2016) 0.75
Medicinal plants with potential anti-arthritic activity. J Intercult Ethnopharmacol (2015) 0.75
A review of pomegranate in prostate cancer. Prostate Cancer Prostatic Dis (2017) 0.75
Pomegranate for Prevention and Treatment of Cancer: An Update. Molecules (2017) 0.75
Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat (2005) 3.23
Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J Urol (2006) 3.02
Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer (2010) 2.62
Consensus conference on breast conservation. J Am Coll Surg (2006) 2.17
Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol (2004) 2.12
Repair of aortic arch and the impact of cross-clamping time, New York Heart Association stage, circulatory arrest time, and age on operative outcome. Interact Cardiovasc Thorac Surg (2007) 2.09
Evaluation of Perioperative Medication Errors and Adverse Drug Events. Anesthesiology (2016) 2.05
Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol (2010) 2.04
Atrial fibrillation ablation outcome is predicted by left atrial remodeling on MRI. Circ Arrhythm Electrophysiol (2013) 1.96
Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase. Breast Cancer Res Treat (2006) 1.95
Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res (2006) 1.89
The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res (2004) 1.80
Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res (2003) 1.76
Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol (2009) 1.74
Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem (2006) 1.72
Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer (2004) 1.67
Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res (2005) 1.66
Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat (2002) 1.60
Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res (2005) 1.58
Is percutaneous nephrolithotomy in solitary kidneys safe? Urology (2013) 1.55
The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol (2003) 1.51
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J (2009) 1.48
Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids (2005) 1.46
Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. J Steroid Biochem Mol Biol (2005) 1.45
Snapshot of transurethral resection of bladder tumours in the United Kingdom Audit (STUKA). BJU Int (2013) 1.44
The learning curve in sentinel node biopsy: the ALMANAC experience. Ann Surg Oncol (2004) 1.44
Expression of peroxisome-proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int J Cancer (2003) 1.44
Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses. Cochrane Database Syst Rev (2016) 1.39
Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer. Clin Exp Metastasis (2004) 1.37
Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer. Eur J Cancer (2004) 1.34
Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis. Oncol Rep (2007) 1.34
The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol (2008) 1.32
Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND. Ann Surg Oncol (2007) 1.29
The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast (2005) 1.24
Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol (2009) 1.23
The vitamin D receptor in cancer. Proc Nutr Soc (2008) 1.22
Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Clin Cancer Res (2006) 1.22
Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med (2006) 1.21
Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids (2006) 1.20
Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene (2004) 1.20
Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists. J Med Chem (2007) 1.18
Vitamin D receptor signaling mechanisms: integrated actions of a well-defined transcription factor. Steroids (2012) 1.18
Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther (2006) 1.18
Mouse orthotopic models for bladder cancer research. BJU Int (2009) 1.17
Acute kidney injury: taking aim at colistin. Crit Care (2014) 1.16
Involvement of the intermediate filament protein cytokeratin-18 in actin pedestal formation during EPEC infection. EMBO Rep (2004) 1.16
Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res (2005) 1.15
A novel mechanism for the inhibition of NF-kappaB activation in vascular endothelial cells by natural antioxidants. FASEB J (2002) 1.15
Electrical stimulation to restore vestibular function development of a 3-d vestibular prosthesis. Conf Proc IEEE Eng Med Biol Soc (2005) 1.14
Role of routine preoperative lymphoscintigraphy in sentinel node biopsy for breast cancer. Eur J Cancer (2005) 1.14
Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids (2003) 1.14
Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer (2005) 1.12
Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer. Ann Surg Oncol (2007) 1.12
Arthroscopic remplissage with Bankart repair for the treatment of glenohumeral instability with Hill-Sachs defects. Arthroscopy (2011) 1.11
Epidermis instructs skin homing receptor expression in human T cells. Blood (2012) 1.10
KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells. Hum Mol Genet (2011) 1.10
Matriptase is a novel initiator of cartilage matrix degradation in osteoarthritis. Arthritis Rheum (2010) 1.08
Specialist palliative care is more than drugs: a retrospective study of ILD patients. Lung (2012) 1.07
Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol Cancer (2008) 1.07
Shock index: blunt clinical predictions. Crit Care (2013) 1.06
Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Invest New Drugs (2005) 1.06
IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells. Eur J Immunol (2008) 1.06
In Reference to "Partial Epiglottoplasty for Pharyngeal Dysphagia due to Cervical Spine Pathology". Otolaryngol Head Neck Surg (2016) 1.05
Recent advances in sentinel lymph node biopsy for breast cancer. Curr Opin Oncol (2008) 1.04
EspF of enteropathogenic Escherichia coli binds sorting nexin 9. J Bacteriol (2006) 1.04
Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol (2005) 1.03
Epigenetic control of a VDR-governed feed-forward loop that regulates p21(waf1/cip1) expression and function in non-malignant prostate cells. Nucleic Acids Res (2010) 1.03
Pituitary tumor transforming gene binding factor: a new gene in breast cancer. Cancer Res (2010) 1.02
The effects of statins on the progression of atherosclerotic renovascular disease. Nephron Clin Pract (2007) 1.02
Colored cosmetic contact lenses: an unsafe trend in the younger generation. Cornea (2012) 1.02
Expression of interleukin 11 and its receptor and their prognostic value in human breast cancer. Ann Surg Oncol (2006) 1.01
Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases. Breast Cancer Res Treat (2006) 1.01
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr (2011) 1.00
Expression of autocrine motility factor (AMF) and its receptor, AMFR, in human breast cancer. J Histochem Cytochem (2005) 1.00
Relation of left atrial volume from three-dimensional computed tomography to atrial fibrillation recurrence following ablation. Am J Cardiol (2009) 0.99
Identification of VDR-responsive gene signatures in breast cancer cells. Oncology (2007) 0.99
Loss of occludin leads to the progression of human breast cancer. Int J Mol Med (2010) 0.99
Vitamin D has wide regulatory effects on histone demethylase genes. Cell Cycle (2012) 0.99
Biphasic effects of 17-beta-estradiol on expression of occludin and transendothelial resistance and paracellular permeability in human vascular endothelial cells. J Cell Physiol (2003) 0.98
Small volume stage 1B1 cervical cancer: Is radical surgery still necessary? Gynecol Oncol (2012) 0.98
Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis (2003) 0.98
Transcription factor co-repressors in cancer biology: roles and targeting. Int J Cancer (2010) 0.98
Short-term follow-up of pertrochanteric fractures treated using the proximal femoral locking plate. J Orthop Trauma (2014) 0.98
A randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia. Breast J (2005) 0.97
The expression and prognostic value of the guanine nucleotide exchange factors (GEFs) Trio, Vav1 and TIAM-1 in human breast cancer. Int Semin Surg Oncol (2008) 0.97
Inhibition of Helicobacter pylori adhesion to human gastric mucus by a high-molecular-weight constituent of cranberry juice. Crit Rev Food Sci Nutr (2002) 0.97
Transcription factors, chromatin and cancer. Int J Biochem Cell Biol (2008) 0.97
Activation of the transcription factor NF-kappaB by Campylobacter jejuni. Microbiology (2002) 0.97
Pomegranate-mediated chemoprevention of experimental hepatocarcinogenesis involves Nrf2-regulated antioxidant mechanisms. Carcinogenesis (2011) 0.97
Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer. BMC Cancer (2006) 0.96
N-WASP is a putative tumour suppressor in breast cancer cells, in vitro and in vivo, and is associated with clinical outcome in patients with breast cancer. Clin Exp Metastasis (2007) 0.96
Endonasal suture techniques in tip rhinoplasty. Facial Plast Surg Clin North Am (2009) 0.96
The localisation and reduction of nuclear staining of PPARgamma and PGC-1 in human breast cancer. Oncol Rep (2004) 0.96
Vitamin D status and breast cancer risk. Anticancer Res (2006) 0.95
Rapid dereplication of estrogenic compounds in pomegranate (Punica granatum) using on-line biochemical detection coupled to mass spectrometry. Phytochemistry (2004) 0.95
Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion. Carcinogenesis (2010) 0.95